Such amendment to the draft Summary of Product Characteristics for terfenadine 60 mg tablet formulation also applies to the draft Summaries of Product Characteristics of terfenadine 30 mg tablet and 6 mg/ ml oral suspension formulations which were annexed to their respective opinions of November 1997 and therefore are to be revised accordingly.